Johnson & Johnson (NYSE:JNJ) is Hazlett Burt & Watson Inc.’s 9th Largest Position

Hazlett Burt & Watson Inc. boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 7.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 19,040 shares of the company’s stock after acquiring an additional 1,298 shares during the period. Johnson & Johnson accounts for about 1.4% of Hazlett Burt & Watson Inc.’s portfolio, making the stock its 9th largest holding. Hazlett Burt & Watson Inc.’s holdings in Johnson & Johnson were worth $3,082,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. purchased a new position in Johnson & Johnson during the 1st quarter worth $765,000. Shariaportfolio Inc. grew its holdings in Johnson & Johnson by 2.3% in the 1st quarter. Shariaportfolio Inc. now owns 14,655 shares of the company’s stock valued at $2,318,000 after buying an additional 325 shares during the period. Prosperity Consulting Group LLC increased its holdings in shares of Johnson & Johnson by 9.3% during the 1st quarter. Prosperity Consulting Group LLC now owns 11,255 shares of the company’s stock worth $1,780,000 after buying an additional 957 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Johnson & Johnson by 11.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 563,628 shares of the company’s stock worth $86,265,000 after buying an additional 55,653 shares during the period. Finally, Centric Wealth Management grew its stake in shares of Johnson & Johnson by 25.3% in the first quarter. Centric Wealth Management now owns 3,592 shares of the company’s stock valued at $519,000 after buying an additional 725 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several research analyst reports. TD Securities reduced their price objective on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. TD Cowen dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.93.

Johnson & Johnson Stock Down 1.2 %

NYSE JNJ opened at $158.24 on Tuesday. The company has a market capitalization of $380.98 billion, a P/E ratio of 22.90, a price-to-earnings-growth ratio of 2.84 and a beta of 0.53. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The stock’s 50-day moving average price is $163.18 and its 200-day moving average price is $155.68. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.66 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.13%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.